Alkem Laboratories has announced record-high EBITDA performance alongside robust revenue growth for the fourth quarter and full financial year 2025-26, driven by strong domestic and international sales expansion. The company reported these standalone and consolidated financial results on May 28, 2026, following a Board of Directors meeting in Mumbai.
For the fourth quarter ended March 31, 2026, Alkem posted total revenue from operations of ₹36,033 million, marking a year-on-year growth of 14.6 percent. India sales stood at ₹23,245 million with 8.8 percent YoY growth, while international sales reached ₹12,223 million, registering a strong 25.4 percent YoY increase. The company’s EBITDA for Q4 FY26 surged 32.2 percent YoY to ₹5,174 million, resulting in an EBITDA margin of 14.4 percent compared to 12.4 percent in Q4 FY25. Profit before tax, before exceptional items, grew 40.7 percent YoY to ₹5,578 million. However, net profit after non-controlling interest declined 22.7 percent to ₹2,365 million, impacted by exceptional items including ₹602.7 million liability towards gratuity and leave encashment and ₹747 million impairment of real estate investments.
For the full financial year 2026, Alkem achieved total revenue from operations of ₹147,123 million, reflecting 13.5 percent YoY growth. India sales contributed ₹98,514 million with 9.7 percent growth, while international sales delivered ₹46,810 million with 22.5 percent YoY expansion. The company recorded its highest-ever EBITDA of ₹30,052 million for FY26, translating to an EBITDA margin of 20.4 percent versus 19.4 percent in FY25, representing a 19.6 percent YoY growth. Profit before tax after exceptional items stood at ₹28,709 million, up 13.6 percent YoY, while net profit after non-controlling interest grew 6.3 percent to ₹23,018 million. R&D expenses for FY26 were ₹6,173 million, accounting for 4.2 percent of total revenue.
Commenting on the results, Dr. Vikas Gupta, CEO of Alkem, stated that the company recorded its highest-ever EBITDA in FY26, reaffirming the strength of its growth strategy, execution, and operational rigor. He highlighted that top-line growth was broad-based with both domestic branded generics and international business delivering strong growth, while improving business mix, operating leverage, and cost discipline drove meaningful margin expansion. Dr. Gupta added that the company enters FY27 on a firm foundation with expectations of healthy growth supported by increasing contribution from chronic therapies and a differentiated launch pipeline for international markets.
In domestic operations, Alkem outperformed the Indian Pharmaceutical Market during Q4 FY26, registering 11.1 percent growth versus IPM’s 10.1 percent, according to IQVIA data. The acute segment grew 10.0 percent compared to IPM’s 7.7 percent, while the chronic segment expanded 16.1 percent against IPM’s 13.6 percent. The company outperformed IPM across six key focused therapies, with dermatology growing approximately 2.0 times IPM, gastro-intestinal 1.8 times, pain 1.7 times, vitamins-minerals-nutrients 1.6 times, respiratory 1.6 times, and anti-diabetic 1.4 times. For the full year FY26, Alkem’s domestic sales contribution to total sales was 67.8 percent compared to 70.2 percent in FY25.
The international business demonstrated strong momentum in Q4 FY26, with US sales reaching ₹7,681 million, up 26.2 percent YoY, and contributing 21.7 percent to total sales. Non-US sales stood at ₹4,543 million with 24.1 percent YoY growth, contributing 12.8 percent to total sales. During the quarter, the company filed five ANDAs and received four ANDA approvals for the US market. For the full year, US sales totaled ₹29,845 million with 20.3 percent YoY growth, while non-US sales reached ₹16,964 million, up 27.4 percent. As of March 31, 2026, Alkem had filed 192 ANDAs, two NDAs, and one BLA with the USFDA, receiving approvals for 167 ANDAs, including 19 tentative approvals and two NDAs. The company launched 11 products during FY26.
The company’s manufacturing facilities continue to maintain regulatory compliance, with the Baddi formulations facility receiving an Establishment Inspection Report in June 2024, while the Taloja R&D bioequivalence center and California API facility are awaiting EIRs with no observations received. The Daman formulations facility received a Form 483 with seven observations in April 2026, with an audit response under submission.
